Future Science Group
Supplementary Table 1.docx (18.5 kB)

Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma - Supplementary Table 1

Download (18.5 kB)
posted on 2023-04-12, 11:03 authored by Enes Erul, Deniz C Guven, Yakup Ozbay, Ahmet Y Altunbulak, Alper Kahvecioglu, Fatih Ercan, Muhammed F Yesil, Mete T Ucdal, Mustafa Cengiz, Gozde Yazici, Oguz Kuscu, Nilda Suslu, Ibrahim Gullu, Mehmet R Onur, Sercan Aksoy

Background: We aimed to evaluate the effect of sarcopenia on survival in head and neck squamous

cell carcinoma patients treated with chemoradiotherapy. Materials & methods: Disease-free survival and

overall survival were compared according to cervical computed tomography for radiotherapy in 123

sarcopenic and non-sarcopenic patients with locally advanced head and neck squamous cell carcinoma

treated with chemoradiotherapy with weekly cisplatin. Results: In multivariate analyses, pretreatment

sarcopenia was associated with lower disease-free survival (hazard ratio: 2.60; 95% CI: 1.38–4.87; p = 0.003)

and overall survival (hazard ratio: 2.86; 95% CI: 1.40–5.85; p = 0.004). Sarcopenic patients experienced more

frequent radiotherapy-related toxicities and platinum-related side effects than non-sarcopenic patients.

Conclusion: Sarcopenia could be a potential biomarker to predict prognosis and treatment toxicity in head

and neck squamous cell carcinoma.


Usage metrics

    Future Science Group


    Ref. manager